According to Fortune Business Insights, the global gene therapy market size was valued at USD 4.29 billion in 2025 and is projected to grow from USD 5.20 billion in 2026 to USD 11.33 billion by 2034, exhibiting a CAGR of 10.20% during the forecast period. North America dominated the global market with a market share of 24.6% in 2025.
The global gene therapy market is witnessing remarkable growth due to increasing advancements in genetic engineering, rising prevalence of rare genetic disorders, and growing investments in biotechnology research. Gene therapy has emerged as a transformative treatment approach that modifies or replaces defective genes to treat or prevent diseases, offering long-term therapeutic benefits for patients suffering from inherited and acquired disorders.
Information Source: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243
Market Drivers
One of the major factors driving market growth is the increasing number of regulatory approvals for gene therapies targeting rare diseases and genetic disorders. Growing awareness regarding personalized medicine and advancements in viral and non-viral vector technologies are further accelerating adoption. In addition, substantial investments from pharmaceutical companies, biotechnology firms, and government organizations are supporting research and commercialization activities.
The rising prevalence of genetic disorders such as hemophilia, muscular dystrophy, cystic fibrosis, and inherited retinal diseases has created a strong demand for innovative treatment solutions. Gene therapy offers the potential for long-lasting or even curative outcomes, making it an attractive alternative to traditional therapies.
Technological Advancements Supporting Growth
Continuous innovations in gene-editing technologies, including CRISPR-Cas9, zinc finger nucleases, and TALENs, are significantly enhancing the effectiveness and precision of gene therapies. Researchers are increasingly focusing on improving delivery mechanisms and reducing treatment-related risks, thereby expanding the scope of gene therapy applications.
The development of advanced viral vectors such as adeno-associated viruses (AAVs) and lentiviral vectors has improved gene transfer efficiency, contributing to better clinical outcomes. These technological advancements are expected to create new growth opportunities for market participants over the coming years.
Segment Analysis
Based on product, the market includes approved therapies such as Zolgensma, Luxturna, Roctavian, and others. The growing adoption of commercially approved gene therapies is driving revenue generation across healthcare systems worldwide.
By vector type, the market is segmented into viral vectors and non-viral vectors. Viral vectors currently account for a significant market share owing to their high efficiency in delivering therapeutic genes into target cells.
Based on indication, the market serves genetic disorders, ophthalmology, hematology, oncology, and other therapeutic areas. Genetic disorders remain a key application segment due to the increasing number of approved treatments and clinical trials.
By end user, hospitals and clinics represent a major market segment due to the specialized infrastructure and expertise required for administering gene therapies.
Regional Insights
North America remains the leading regional market, supported by strong healthcare infrastructure, favorable regulatory frameworks, and substantial investments in research and development. The presence of major biotechnology and pharmaceutical companies further strengthens the region's market position.
Europe also represents a significant market, driven by increasing clinical research activities, government support, and rising adoption of advanced therapies. Meanwhile, the Asia Pacific region is expected to witness rapid growth due to improving healthcare infrastructure, growing awareness, and expanding biotechnology industries in countries such as China, Japan, and India.
Competitive Landscape
The gene therapy market is highly competitive, with leading companies focusing on strategic collaborations, acquisitions, product launches, and research investments to strengthen their market positions. Organizations are actively expanding their clinical pipelines and seeking regulatory approvals for innovative therapies across multiple disease indications.
Key Players
- Novartis AG
- CSL
- F. Hoffmann-La Roche Ltd.
- BioMarin Pharmaceutical Inc.
- Gilead Sciences, Inc.
- bluebird bio, Inc.
- Pfizer Inc.
- Sarepta Therapeutics, Inc.
- Orchard Therapeutics plc
- UniQure N.V.
Future Outlook
The future of the gene therapy market appears promising as scientific advancements continue to improve treatment efficacy and accessibility. Growing clinical trial activity, increasing regulatory support, and expanding applications in oncology and rare diseases are expected to fuel market growth. As research progresses and manufacturing capabilities improve, gene therapy is likely to become an integral component of modern healthcare, offering transformative treatment options for patients worldwide.
FAQs
1. What is the size and share of the global gene therapy market?
According to Fortune Business Insights, the global gene therapy market was valued at USD 4.29 billion in 2025 and is projected to grow from USD 5.20 billion in 2026 to USD 11.33 billion by 2034 at a CAGR of 10.20%. North America held a dominant market share of 24.6% in 2025.
2. What factors are driving the growth of the gene therapy market?
Key growth drivers include increasing prevalence of genetic disorders, advancements in gene-editing technologies, rising regulatory approvals, growing investments in biotechnology research, and expanding applications of personalized medicine.
3. Who are the major players in the gene therapy market?
Major companies operating in the market include Novartis AG, CSL, F. Hoffmann-La Roche Ltd., BioMarin Pharmaceutical Inc., Gilead Sciences, Inc., bluebird bio, Pfizer Inc., Sarepta Therapeutics, Orchard Therapeutics, and UniQure N.V.
Top comments (0)